NanoViricides Begins Phase II Trial of Oral Ebola Treatment NV-387 in DRC
NanoViricides, Inc. has initiated a Phase II clinical trial for NV-387 oral gummies to treat Bundibugyo Ebolavirus and other strains in the Democratic Republic of Congo. Launched on September 23, ... Read More